Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, Syngene International has informed that the US Food and Drug Administration (FDA) has conducted its pre-approval inspection of the Biologics facility at Bangalore from November 07, 2022 till November 15, 2022. The inspection was completed successfully without 483 observations. The above-mentioned information will also be available on website of the Company www.syngeneintl.com.
The above information is a part of company’s filings submitted to BSE.
